Abstract Details

Title Is having multiple sclerosis associated with reproductive milestones in women?

Topic Multiple Sclerosis

Presentation(s) MS and CNS Inflammatory Disease Posters (7:00 AM-5:00 PM)

Poster/Presentation
Number 174

Objective To compare the reproductive history characteristics between women with multiple sclerosis (MS) and control women.

Background The reproductive period from menarche to natural menopause often marks the active inflammatory disease period in MS. The relationship between sex hormones and the immune system potentially plays an important role in the disease course in women with MS.

Design/Methods

A case-control study of women with MS and age-matched control women from a population-based cohort was conducted. Menarche age, number of full-term and incomplete pregnancies, menopause age and menopause type were compared between 137 postmenopausal women with MS and 396 matched control women.

Results Menarche age was similar in women with MS and control women (median, interquartile range [IQR]; MS 13 years, 12-13.2; controls 12 years, 12-13; p=0.306). Women with MS had lower number of pregnancies than control women (median, IQR; MS 2, 1-3; controls 3, 2-4; p=0.001) and lower number of full-term pregnancies than control women (median, IQR; MS 2, 1-3; controls 3, 2-3; p<0.001). Age at menopause was not different between MS and controls (median, IQR; MS 49 years, 44.5-52; controls 50 years, 43-52; p=0.791). Age at natural menopause was similar between MS and controls as well (median, IQR; MS 50 years, 48-52; controls 51 years, 49-53; p=0.476). Non-natural menopause was more frequent in women with MS (40.7%) compared to control women (30.1%) (p=0.030).

Conclusions The natural reproductive milestones, age at menarche and age at natural menopause, were not different between women with MS and controls. The age at natural menopause was similar to previous studies on MS and to the mean age of 51 in Western populations. Overall, MS does not seem to directly impact the natural reproductive milestones in women. However, in addition to surgical menopause, immunomodulation may be associated with the higher frequency of non-natural menopause in MS.

Authors/Disclosures
Burcu Zeydan, MD (Mayo Clinic) PRESENTER	The institution of Dr. Zeydan has received research support from National Institutes of Health.
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Walter A. Rocca, MD, MPH	The institution of Dr. Rocca has received research support from National Institute on Aging - NIH. The institution of Dr. Rocca has received research support from National Heart, Lung, and Blood Institute - NIH.
Mark Keegan, MD, FAAN (Mayo Clinic)	Dr. Keegan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Keegan has received publishing royalties from a publication relating to health care. Dr. Keegan has received publishing royalties from a publication relating to health care.
Brian G. Weinshenker, MD, FAAN (University of Virginia Health System)	Dr. Weinshenker has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Weinshenker has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Pharmaceuticals. Dr. Weinshenker has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Zenas Pharma. Dr. Weinshenker has received research support from Guthy Jackson Charitable Foundation. Dr. Weinshenker has received intellectual property interests from a discovery or technology relating to health care.
Kejal Kantarci, MD (Mayo Clinic)	The institution of Dr. Kantarci has received research support from Eli Lilly. The institution of Dr. Kantarci has received research support from NIH. The institution of Dr. Kantarci has received research support from ADDF. The institution of Dr. Kantarci has received research support from Eisai. The institution of Dr. Kantarci has received research support from BioArctic.
Orhun H. Kantarci, MD	Dr. Kantarci has nothing to disclose.

��ɫ��

��ɫ��